Posters presented by Investigators:
Basic Studies
Clinical
Investigations
Treatments
Basic Studies
| CHARVET Benjamin | France | A high-molecular weight and soluble hexameric form of endogenous retroviral protein, pHERV-W ENV, is specifically extracted from demyelinating MS lesions and can be detected in sera from active MS patients - ID24 View poster - Abstract |
| KAP Yolanda | Netherlands | Evaluating the effect of cladribine on marmoset B- and T-cell proliferation and survival - ID46 View poster - Abstract |
| KÜRY Patrick | Germany | Microglial-dependent neurodegeneration in multiple sclerosis is fueled by the pHERV-W envelope protein - ID36 View poster - Abstract |
| VERMERSCH Patrick | France | Comparing patient and healthcare professional perceptions on multiple sclerosis management and care – a sub-analysis of disease progression perspectives (Encore. First published at ECTRIMS 2018) - ID62 View poster - Abstract |
| BOYKO Alexey | Russia | Rationale and feasibility of a phase IV study (CLASSIC MS) assessing long-term efficacy outcomes for patients with multiple sclerosis treated with Cladribine Tablets in the phase III trials - ID57 View poster - Abstract |
| BUTERA Calogera | Italy | Focal spasticity in multiple sclerosis: treatment-goal attainment evaluation after botulinum toxin type A therapy and physical rehabilitation - ID80 Abstract |
| CAMPBELL Nolan | United States | Evaluating the efficacy and safety of 6-week extended interval dosing of natalizumab via a prospective, controlled, randomized, open-label, rater-blinded phase 3b study - ID71 View poster - Abstract - Poster presentation recording |
| COMI Giancarlo | Italy | Effect of Teriflunomide in Subgroups Defined by Prior Treatment: Pooled Analysis of the Phase 2 study and the Phase 3 TEMSO, TOWER, and TENERE Studies - ID51 View poster - Abstract |
| COOK Stuart | United States | Lymphopenia rates in CLARITY/CLARITY Extension are unrelated to disease activity at baseline - ID39 View poster - Abstract |
| COOK Stuart | United States | Updated safety analysis of Cladribine Tablets (CT) in the treatment of patients with multiple sclerosis (MS) - ID40 View poster - Abstract |
| DE STEFANO Nicola | Italy | Rapid reduction of lesion accumulation in specific white matter tracts as assessed by lesion mapping in patients with relapsing-remitting multiple sclerosis treated with interferon beta-1a - ID63 View poster - Abstract |
| DE VOER Gert | Netherlands | Relationship between cognitive status and depression, anxiety, fatigue, adherence, or disability in patients with RRMS treated with interferon beta-1a under real-life conditions - ID60 Abstract |
| EDWARDS Keith | United States | NfL elevation may precede clinical exacerbation - ID76 View poster - Abstract |
| EUBANKS James | United States | Final Results of a Placebo Controlled, Phase 2a Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS) - ID77 View poster - Abstract - Poster presentation recording |
| FREEDMAN Mark | Canada | Long-Term Efficacy and Safety of Teriflunomide: An Analysis of Pooled Clinical Trials - ID50 View poster - Abstract |
| GIOVANNONI Gavin | United Kingdom | An exploratory analysis of the efficacy of Cladribine Tablets 3.5mg/kg (CT3.5) in patients with relapsing multiple sclerosis (RMS) stratified according to age above and below 45 years in the CLARITY study - ID38 View poster - Abstract |
| GIOVANNONI Gavin | United Kingdom | Durability of No Evidence of Disease Activity-3 (NEDA-3) status in patients with relapsing multiple sclerosis (RMS) receiving Cladribine Tablets 3.5 mg/kg (CT3.5): CLARITY Extension - 66 View poster - Abstract |
| GLANZMAN Robert | Switzerland | GNbAC1 shows efficacy on MRI measures of neurodegeneration in relapsing-remitting MS patients over 48 weeks - ID56 View poster - Abstract - Poster presentation recording |
| HARTY Gerard | United States | Subcutaneous Interferon beta-1a, 10-Year Results from the United Kingdom Multiple Sclerosis Risk Sharing Scheme - ID44 View poster - Abstract |
| HELLWIG Kerstin | Germany | Pregnancy and Infant Outcomes with Interferon Beta: Data from the European Interferon Beta Pregnancy Registry and Population Based Registries in Finland and Sweden - ID59 View poster - Abstract |
| MAYR Martin | Germany | PatientConcept – the modern method for the implementation of Risk Management Plans - ID49 View poster - Abstract - Poster presentation recording |
| MONTALBAN Xavier | Canada | Primary analysis of a randomised, placebo-controlled, phase 2 study of the oral Bruton’s tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis - ID37 View poster - Abstract |
| MONTALBAN Xavier | Canada | FLOODLIGHT: Smartphone-Based Self-Monitoring is Accepted by Patients and Provides Meaningful, Continuous Digital Outcomes Augmenting Conventional In-Clinic Multiple Sclerosis Measures - ID58 View poster - Abstract |
| NIKOLAIDIS Ioannis | Greece | The impact of fatigue and depression on quality of life in multiple sclerosis patients in a tertiary MS Center View poster - Abstract |
| ROSJO Egil |
Norway | Effect of vitamin D supplementation on axonal damage in relapsing-remitting multiple sclerosis - ID31 View poster - Abstract |
| SCHIPPLING Sven | Switzerland | CLARITY: An analysis of severity and frequency of relapses in patients with relapsing remitting multiple sclerosis (RRMS) treated with Cladribine Tablets 3.5 mg/kg (CT3.5) or placebo (PBO) - ID45 View poster - Abstract |
| SIRBU Carmen Adella |
Romania | Multiple Sclerosis and Brain Tumors, a Challenging Diagnostic - case reports - ID18 View poster - Abstract |
| VERMERSCH Patrick | France | Sustained efficacy in relapsing remitting multiple sclerosis (RRMS) following switch to placebo treatment from Cladribine Tablets 3.5 mg/kg (CT3.5) in patients with high disease activity (HDA) at baseline - ID41 View poster - Abstract |
| VOLLMER Timothy | United States | Design of a study to evaluate the safety of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis Authors - ID26 View poster - Abstract |
Investigations
| WILLEKENS Barbara | Belgium | Safety and feasibility of a tolerogenic dendritic cell-based treatment of multiple sclerosis (MS): a comparison of intranodal and intradermal cell administration in two phase I clinical trials - ID28 View poster - Abstract - Poster presentation recording |
Treatments
| AKTAS Orhan | United States | Ocrelizumab Compassionate Use Program for Patients with Primary Progressive Multiple Sclerosis in Germany - ID54 View poster - Abstract |
| BROCHET Bruno | France | EMBLE-PLUS Study Design: An Investigation of Shortened Ocrelizumab Infusion Time on Infusion-Related Reactions in Patients with Relapsing Multiple Sclerosis From the Phase IIIb ENSEMBLE-PLUS Study - ID68 View poster - Abstract |
| HARTUNG Hans-Peter | Germany | Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study) ) - ID42 View poster - Abstract |
| JÄRVINEN Elina | Finland | Interferon β-1a s.c tiw treatment response and disability progression - ID55 View poster - Abstract |
| RICHTER Joachim | Germany | Design of the non-interventional, prospective study CLADQoL (CLADribine Tablets – evaluation of Quality of Life) - ID21 View poster - Abstract |
| RICHTER Joachim | Germany | Design of the non-interventional, prospective study CLEVER (CLadribine Tablets – EValuation of thERapy satisfaction) - ID22 View poster - Abstract |
| VAN WIJMEERSCH Bart | Belgium | No Correlation Between Lymphocyte Pharmacodynamics and Autoimmune Adverse Events Following Alemtuzumab Treatment in Patients With Relapsing-Remitting Multiple Sclerosis - ID43 View poster - Abstract |
| WILLEKENS Barbara | Belgium | The BELTRIMS registry: a unique Belgian registry on real-world safety and efficacy data of MS patients treated with new DMTs in Belgium - ID27 View poster - Abstract - Poster presentation recording |
